Related Experiment Video

Updated: Jun 13, 2026

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Early identification of cardiovascular risk using genomics and proteomics

Iftikhar J Kullo1, Leslie T Cooper

  • 1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. kullo.iftikhar@mayo.edu

Nature Reviews. Cardiology
|May 5, 2010
PubMed

Insights

Coronary heart disease (CHD) is a growing global health concern. Genomics and proteomics offer new ways to assess cardiovascular risk and personalize treatments for atherosclerosis.

Area of Science:

  • Cardiovascular Medicine
  • Genomics
  • Proteomics

Background:

  • Coronary heart disease (CHD) is a leading cause of global mortality and morbidity.
  • Atherosclerosis, the underlying pathology of CHD, involves complex genetic and environmental factors.
  • Current risk assessment for CHD has limitations in predicting individual outcomes.

Purpose of the Study:

  • To discuss the role of genomics and proteomics in cardiovascular risk assessment.
  • To explore the potential of a multimarker approach for identifying atherogenesis pathways.
  • To highlight the feasibility of individualized risk stratification and targeted therapy for CHD.

Main Methods:

  • Review of recent advances in genomics and proteomics relevant to cardiovascular disease.
  • Discussion of how these technologies can identify novel risk factors.
  • Exploration of a multimarker strategy for assessing composite risk profiles.

Main Results:

  • Genomics and proteomics are expected to identify numerous new risk factors for CHD.
  • Individualized risk assessment using genomic and proteomic markers may become feasible.
  • A multimarker approach can reveal alterations in atherogenesis pathways.

Conclusions:

  • Genomics and proteomics are poised to revolutionize cardiovascular risk assessment.
  • Personalized medicine approaches, including targeted therapies, are likely to improve CHD outcomes.
  • A shift towards a multimarker, pathway-focused strategy is essential for advancing CHD prevention and treatment.

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...